| Primary |
| Multiple Sclerosis |
56.8% |
| Relapsing-remitting Multiple Sclerosis |
19.5% |
| Premedication |
2.4% |
| Secondary Progressive Multiple Sclerosis |
2.4% |
| Depression |
2.3% |
| Hypertension |
1.9% |
| Pain |
1.9% |
| Product Used For Unknown Indication |
1.9% |
| Gastrooesophageal Reflux Disease |
1.6% |
| Headache |
1.1% |
| Prophylaxis |
1.1% |
| Fatigue |
1.0% |
| Multiple Sclerosis Relapse |
1.0% |
| Muscle Spasms |
1.0% |
| Progressive Multiple Sclerosis |
1.0% |
| Prenatal Care |
0.7% |
| Anxiety |
0.6% |
| Convulsion |
0.6% |
| Dermatitis |
0.6% |
| Drug Use For Unknown Indication |
0.6% |
|
| Death |
9.8% |
| Multiple Sclerosis |
8.5% |
| Pyrexia |
8.5% |
| Pain |
7.9% |
| Depressed Mood |
6.7% |
| Injection Site Erythema |
6.7% |
| Asthenia |
4.9% |
| Influenza Like Illness |
4.9% |
| Chills |
4.3% |
| Convulsion |
4.3% |
| Fatigue |
4.3% |
| Depression |
3.7% |
| Headache |
3.7% |
| Injection Site Atrophy |
3.7% |
| Cellulitis |
3.0% |
| Loss Of Consciousness |
3.0% |
| Mobility Decreased |
3.0% |
| Multiple Sclerosis Relapse |
3.0% |
| Skin Plaque |
3.0% |
| Vomiting |
3.0% |
|
| Secondary |
| Multiple Sclerosis |
33.4% |
| Relapsing-remitting Multiple Sclerosis |
16.6% |
| Primary Progressive Multiple Sclerosis |
10.6% |
| Premedication |
5.8% |
| Product Used For Unknown Indication |
5.4% |
| Headache |
3.2% |
| Depression |
3.0% |
| Drug Use For Unknown Indication |
3.0% |
| Foetal Exposure During Pregnancy |
2.4% |
| Prophylaxis |
2.4% |
| Prenatal Care |
2.2% |
| Secondary Progressive Multiple Sclerosis |
2.0% |
| Mitral Valve Prolapse |
1.6% |
| Nausea |
1.6% |
| Hypertension |
1.4% |
| Diabetes Mellitus |
1.2% |
| Eye Pain |
1.2% |
| Sleep Disorder Therapy |
1.2% |
| Pain |
1.0% |
| Breakthrough Pain |
0.8% |
|
| White Blood Cell Count Decreased |
18.9% |
| Headache |
7.1% |
| Injection Site Erythema |
7.1% |
| Mitral Valve Prolapse |
6.3% |
| Mobility Decreased |
6.3% |
| Asthenia |
5.5% |
| Fatigue |
5.5% |
| Sensory Disturbance |
5.5% |
| Hemicephalalgia |
4.7% |
| Pain |
4.7% |
| Depression |
3.9% |
| Convulsion |
3.1% |
| Influenza Like Illness |
3.1% |
| Loss Of Consciousness |
3.1% |
| Xerophthalmia |
3.1% |
| Abscess |
2.4% |
| Bedridden |
2.4% |
| Catheter Placement |
2.4% |
| Cholelithiasis |
2.4% |
| Dehydration |
2.4% |
|
| Concomitant |
| Multiple Sclerosis |
24.4% |
| Relapsing-remitting Multiple Sclerosis |
15.1% |
| Product Used For Unknown Indication |
9.3% |
| Convulsion |
7.0% |
| Progressive Multiple Sclerosis |
7.0% |
| Imaging Procedure |
4.7% |
| Sinusitis |
4.7% |
| Back Pain |
3.5% |
| Insomnia |
3.5% |
| Pain |
3.5% |
| Depression |
2.3% |
| Mobility Decreased |
2.3% |
| Muscle Spasms |
2.3% |
| Neuralgia |
2.3% |
| Smoking Cessation Therapy |
2.3% |
| Angiogram |
1.2% |
| Bladder Disorder |
1.2% |
| Diabetes Mellitus |
1.2% |
| Drug Use For Unknown Indication |
1.2% |
| Fatigue |
1.2% |
|
| Multiple Sclerosis Relapse |
12.0% |
| Amenorrhoea |
8.0% |
| Jaundice |
8.0% |
| Labyrinthitis |
8.0% |
| Red Blood Cell Count Increased |
8.0% |
| Visual Impairment |
8.0% |
| Abdominal Pain Upper |
4.0% |
| Back Pain |
4.0% |
| Basal Cell Carcinoma |
4.0% |
| Dementia With Lewy Bodies |
4.0% |
| Drug Eruption |
4.0% |
| Infection |
4.0% |
| Multiple Sclerosis |
4.0% |
| Skin Discolouration |
4.0% |
| Skin Necrosis |
4.0% |
| Status Epilepticus |
4.0% |
| Vision Blurred |
4.0% |
| Weight Increased |
4.0% |
|
| Interacting |
| Multiple Sclerosis Relapse |
100.0% |
|
| Drug Interaction |
50.0% |
| Multiple Sclerosis Relapse |
50.0% |
|
